TelomelysinR-Radiation Combination Therapy Clinical Study Data Presented at the 2018 Annual Meeting of JSMO

Press Release ONCOLYS BIOPHARMA INC. (TSE Mothers: 4588) 19 July 2018 Data on Telomelysin® - Radiation Combination Therapy Clinical Study Conducted by Okayama University Presented at the 2018 Annual Meeting of JSMO Tokyo, JAPAN: The data of a clinical study on combination therapy using Oncolys Biopharma’s oncolytic virus Telomelysin® (OBP-301) and radiation, for esophageal cancer patients who are refractory to existing cancer treatments such as surgery and definitive chemotherapy, conducted by a group of experts led by Dr. Toshiyoshi Fujiwara, Okayama University, was presented on Thursday 19h July 2018 at International Symposium 1 in the 2018 Japanese Society of Medical Oncology Annual Meeting (“JSMO”) in Kobe, Hyogo prefecture, Japan. The responses included 8 complete response (CR) and 3 partial responses (PR) out of 13 patients enrolled in the study, which altogether accounts for 84.6% of patients responded to the treatment. There has been no serious adverse effects reported to date. Details of the symposium are as below: 【The 2018 JSMO Annual Meeting】 Time & Date: Thu 19 July 2018, 12:30 – 14:00 (International Symposium) Venue: Kobe International Exhibition Hall, Room 2 Symposium Theme: New treatment modality for GI cancer Chairs : Kohei Shitara（Dept. of Gastrointestinal Oncology, National Cancer Center Hospital East） Josep Tabernero（Medical Oncology Dept., Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain） Speakers: Josep Tabernero（Medical Oncology Dept., Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain） Yoon-Koo Kang（Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea） Yasuhiro Matsumura（Division of Developmental Therapeutics, EPOC, National Cancer Center） Toshiyoshi Fujiwara（Dept. of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences） Dr. Fujiwara’s Presenation Theme: "Multidisciplinary oncolytic virotherapy for gastrointestinal cancer" ※The 2018 Annual Meeting of JSMO HP: http://www.congre.co.jp/jsmo2018/ # # # About Telomelysin® (OBP-301): Telomelysin® is an oncolytic adenovirus in which gene is modified to be able to selectively replicate in cancer cells by introducing human telomerase reverse transcriptase (hTERT) promotor. Oncolytic adenovirus has much potential for cancer immunotherapy because its viral replication is highly immunogenic, and oncolysis induced by such virus releases tumor epitopes and provides costimulatory danger signals. From the result of phase I clinical trial in the US, Oncolys obtained promising data showing abscopal effect in melanoma patients after single injection into one single tumor and found that not only increasing infiltration of CD8 and antigen presenting cells but diminishing Treg cells in injected tumor site. Clinical Research: Co-development with Medigen Biotechnology Corporation: esophageal cancer (Phase I, in combination with radiotherapy, Japan); hepatocellular cancer (Phase I/II, Taiwan/South Korea); melanoma (Phase II, USA); and solid tumors (clinical investigation, in combination with pembrolizumab, NCCHE, Japan) About Oncolys BioPharma Inc.: Oncolys BioPharma is a TSE Mothers-listed biopharmaceutical company with focuses on the development of novel biologics for the treatment of cancer and infectious diseases. The company’s lead product for the treatment of cancer, Telomelysin® (OBP-301), is based on replication-competent oncolytic virus, and is being tested in Phase I/II clinical trial in Asia and Phase II in the USA, for various solid tumors. A novel cancer diagnostic product, TelomeScan® (OBP-401/1101), is expected to be effective in detecting various types of cancer and inflammatory diseases and adopted in several private practices. The company also has a major program OBP-601 (Censavudine) for infectious diseases, for which it completed Phase II clinical trial in the U.S. for HIV/AIDS therapy, supported by BMS. For more information, please visit http://www.oncolys.com/en/ Oncolys BioPharma Inc. Mie Yamazaki Investors Relations & Corporate Communications Tel: +81 (0) 5472 1578 Email: [email protected]

The release as fetched from its publisher. oncolys.com ↗